NEW YORK (GenomeWeb News) – Nuclea Biotechnologies today announced the acquisition of a portfolio of six patents and applications related to tissue microarrays for an undisclosed amount.
Nuclea acquired the IP from Laurus Master Fund, a division of Laurus Capital Management. Clinomics Biosciences previously owned the IP and assigned it to Laurus, but since then, the patents have not been maintained, Nuclea said, adding that it plans to petition the US Patent and Trademark Office immediately to revive them.
Nuclea President and CEO Patric Muraca is the inventor of all the technologies in the patent portfolio purchased from Laurus. He was previously the president and COO of Clinomics.
"We believe these patents will allow Nuclea to expand our product offering and drive significant licensing revenue for the company," Muraca said in a statement. "The tissue microarray technologies contained in this portfolio are very useful in specimen analysis, and we are eager to integrate them into our research."